Tool demonstrated generalizability through high predictive performance in international clinical cohort

Differences in age at diagnosis, Breslow thickness, ulceration, mitoses, and site account for 86.5 percent of effect of sex on survival

Higher cumulative dose also linked to reduced rate of isotretinoin retrial in patients with acne aged 12 years or older

In this recurring column, Dermsquared and J.P. Morgan provide tailored financial strategies and investment insights for the dermatology community. Each 500-word article highlights key...

Significantly lower risk for SCC seen in univariable and multivariable analyses, but not in African American patients

Ritlecitinib alone or with narrow-band UVB phototherapy well tolerated and beneficial in nonsegmental vitiligo

Interest in cosmetic procedures significantly predicted by frequent self-viewing behavior

In study, authors describe only two cases of local recurrence among 148 tumors managed by watchful waiting after clinical resolution

Efficacy and safety for scalp psoriasis, seen at week 16, are maintained through week 52

More localized VLD seen in study cohort; 140 of 200 patients had less than 10 percent of body surface area affected

Increased risk seen in association with nine primary cancers, with highest risk at one to five years after diagnosis of primary cancer

CLICK HERE to watch Dr James Del Rosso give his expert clinical insights on VTAMA for atopic dermatitis

Additionally, interim analysis shows that the antiviral is safe but has no effect on pain among adults with mild-to-moderate clade II mpox

CLICK HERE to watch Dr James Del Rosso’s dermatologic deep dive on Bimzelx (bimekizumab) for psoriatic arthritis

The monoclonal antibody treatment is for patients ages 12 years and older

CLICK HERE to watch Dr James Del Rosso provide an in-depth overview of Nemluvio (nemolizumab) for atopic dermatitis

Self-guided cognitive behavioral therapy intervention noninferior to clinician-guided therapy

Risk factors for subsequent neoplasm risk include age 50 years and older at BMT, male sex, post-BMT immunosuppression

FDA Approves VTAMA® (tapinarof) cream, 1% for the Treatment of Atopic Dermatitis in Adults and Children 2 Years of Age and Older

• EFFICACY: In...

Findings for primary tumors of 0.8 to 1.0 mm versus those <0.8 mm

All patients receiving surgery/radiotherapy alone or with chemotherapy had improvement or stability of alopecia with LDOM

Findings seen for children with and without comorbidities, such as asthma, allergic rhinitis, food allergies